Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective, Mathew W. MacCumber, MD, PhD, discusses his poster presentation from the ...

Regenxbio and Clearside Biomedical announced an option and license agreement that will give Regenxbio exclusive worldwide rights to Clearside’s SCS Microinjector for the delivery of RGX-314 to the ...

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator ...

Clearside announced an option and license agreement with Regenxbio Inc (NASDAQ:RGNX), granting the latter worldwide rights to its proprietary in-office SCS Microinjector for the delivery of RGX-314 to ...

Clearside Biomedical presented data on CLS-AX and its SCS delivery platform at the ARVO 2025 Meeting, highlighting treatment advancements for retinal diseases. Clearside Biomedical, Inc. has announced ...

- Webcast and Conference Call Today at 8:00 A.M. ET with Management and Key Opinion Leader and Board-Certified Retinal Specialist, Roger Goldberg, M.D., MBA - ALPHARETTA, Ga., Oct. 09, 2024 (GLOBE ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

Single-cell microinjection represents an innovative way to integrate exogenous material into cells and to extract and transmit cellular components between cells. The effectiveness of any ...

- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy - - IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema - ...